Logo image of AKTX

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Fundamental Analysis

NASDAQ:AKTX - US00972G2075 - ADR

0.8187 USD
+0.09 (+12.15%)
Last: 9/5/2025, 8:00:01 PM
0.7702 USD
-0.05 (-5.92%)
After Hours: 9/5/2025, 8:00:01 PM
Fundamental Rating

1

AKTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. AKTX has a bad profitability rating. Also its financial health evaluation is rather negative. AKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKTX has reported negative net income.
In the past year AKTX has reported a negative cash flow from operations.
In the past 5 years AKTX always reported negative net income.
In the past 5 years AKTX always reported negative operating cash flow.
AKTX Yearly Net Income VS EBIT VS OCF VS FCFAKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -24.09%, AKTX is doing good in the industry, outperforming 73.80% of the companies in the same industry.
Looking at the Return On Equity, with a value of -47.91%, AKTX is in the better half of the industry, outperforming 66.61% of the companies in the same industry.
Industry RankSector Rank
ROA -24.09%
ROE -47.91%
ROIC N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKTX Yearly ROA, ROE, ROICAKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTX Yearly Profit, Operating, Gross MarginsAKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

AKTX has a worse debt/assets ratio than last year.
AKTX Yearly Shares OutstandingAKTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
AKTX Yearly Total Debt VS Total AssetsAKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AKTX has an Altman-Z score of -6.04. This is a bad value and indicates that AKTX is not financially healthy and even has some risk of bankruptcy.
AKTX's Altman-Z score of -6.04 is on the low side compared to the rest of the industry. AKTX is outperformed by 64.58% of its industry peers.
AKTX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
AKTX's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. AKTX is outperformed by 61.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -6.04
ROIC/WACCN/A
WACCN/A
AKTX Yearly LT Debt VS Equity VS FCFAKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

AKTX has a Current Ratio of 0.19. This is a bad value and indicates that AKTX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of AKTX (0.19) is worse than 95.57% of its industry peers.
A Quick Ratio of 0.19 indicates that AKTX may have some problems paying its short term obligations.
The Quick ratio of AKTX (0.19) is worse than 95.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
AKTX Yearly Current Assets VS Current LiabilitesAKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 20.00% over the past year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AKTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.32%
EPS Next 2Y36.55%
EPS Next 3Y22.37%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKTX Yearly Revenue VS EstimatesAKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2032 10M 20M 30M 40M
AKTX Yearly EPS VS EstimatesAKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTX Price Earnings VS Forward Price EarningsAKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTX Per share dataAKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

AKTX's earnings are expected to grow with 22.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.55%
EPS Next 3Y22.37%

More info and screens

0

5. Dividend

5.1 Amount

AKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKARI THERAPEUTICS PLC-ADR

NASDAQ:AKTX (9/5/2025, 8:00:01 PM)

After market: 0.7702 -0.05 (-5.92%)

0.8187

+0.09 (+12.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-17 2025-11-17
Inst Owners0.91%
Inst Owner Change80.93%
Ins Owners34.7%
Ins Owner Change0.01%
Market Cap26.70M
Analysts82.5
Price Target6.12 (647.53%)
Short Float %35.86%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-92.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.33%
EPS NY rev (3m)87.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.79
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.09%
ROE -47.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.43%
ROA(5y)-132.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -6.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y86.32%
EPS Next 2Y36.55%
EPS Next 3Y22.37%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y48.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.32%
OCF growth 3YN/A
OCF growth 5YN/A